Let's have some real talk about total joint procedure volumes in the US.
The rise of GLP-1 receptor agonists like Zepbound and Wegovy isn't a minor blip on the orthopedic radar—it’s triggering a full-scale collision of opposing forces.
As tens of millions of Americans lose weight through medical therapy, executive suites are doubling down on defensive optimism. They want you to believe in a single, comfortable narrative: GLP-1s are a "funnel expander" bringing obese patients down below BMI cutoffs to unlock massive surgical demand.
That is only half the story.
Inside the clinical trenches, a violent tug-of-war is taking place between two competing market forces—and if you read between the lines of recent earnings calls, one side is already pulling hard.
1/ The Case for Expansion: Unlocking BMI-Ineligible Patients
For decades, strict Body Mass Index (BMI) cutoffs—typically capped at 40 by hospitals and ambulatory surgery centers—served as immovable gatekeepers for total joint arthroplasty (TJA). High BMI directly drives up post-operative infection, anesthesia risk, and early implant failure.
Lowering Surgical Barriers: By achieving 15% to 22% body weight reduction without invas...
